Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Small Cell 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9lutetium Lu 177 dotatate 6cabozantinib 6Nivolumab 5Ipilimumab 4fludarabine 3X-Rays 3Phantoms, Imaging 3Etoposide 3Cyclophosphamide 3CTLA-4 Antigen 3pembrolizumab 2olaparib 2aldesleukin 2Lutetium-177 2Lutetium 2Irinotecan 2Cisplatin 2Carboplatin 2trametinib 1tivozanib 1tipifarnib 1selpercatinib 1repotrectinib 1pazopanib 1gallium Ga 68 dotatate 1gallium 68 PSMA-11 1fluorodopa F 18 1fluorocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PT-100 dipeptide × Endocrine × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡